Autoradiographic comparison of in vitro binding characteristics of various tritiated adenosine A2A receptor ligands in rat, mouse and pig brain and first ex vivo results.
The adenosine A(2A) receptor in the basal ganglia is involved in the control of movement and plays a role in movement disorders such as Parkinsonism. Developing ligands to evaluate that receptor by noninvasive methods such as positron emission tomography has a high priority. In vitro radioligand binding guides the selection of ligands for in vivo application. This study measured the binding of the adenosine A(2A) receptor antagonist [(3)H]MSX-2 (3-(3-hydroxypropyl)-8-m-methoxystyryl)-7-methyl-1-propargylxanthine) to rat, mouse and pig brain by autoradiography. Other studies measured binding to membranes from PC12 pheochromocytoma cells. Those binding parameters were compared to those of the adenosine A(2A) receptor antagonist [(3)H]ZM241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino)ethyl)phenol), the adenosine A(2A) receptor agonist [(3)H]CGS21680 (2-[p-(2-carboxyethyl)-phenethylamino]-5'-N-ethylcarboxamidoadenosine) and the unselective adenosine receptor agonist [(3)H]NECA (5'N-ethylcarboxamido)adenosine). The potency order (K(d)) in the three species was [(3)H]ZM241385<[(3)H]MSX-2<[(3)H]NECA<[(3)H]CGS21680. The density of [(3)H]MSX-2 binding sites was greater in the striatum than in the cortex. Preliminary ex vivo experiments showed that by 10min after iv injection, [(3)H]MSX-2 and [(3)H]CGS21680 crossed the blood-brain barrier to the extent of almost 1% ID/g brain tissue, but [(3)H]NECA and [(3)H]ZM241385 to only 0.2% ID/g. The prior administration of unlabeled ZM241385 significantly lowered brain uptake of [(3)H]MSX-2. In conclusion, [(3)H]MSX-2 has a high affinity and sufficient selectivity for the adenosine A(2A) receptor. It penetrates the blood-brain barrier. Sensitivity to photoisomerization is a limitation. Further investigations assess its suitability as a ligand for imaging the brain adenosine A(2A) receptor.
Sihver
Wiebke
W
Institute of Neuroscience and Medicine, INM-5, (Nuclear Chemistry), Research Center Jülich, 52425 Jülich, Germany. w.sihver@fz-juelich.de
Schulze
Annette
A
Wutz
Walter
W
Stüsgen
Stefan
S
Olsson
Ray A
RA
Bier
Dirk
D
Holschbach
Marcus H
MH
D058908:Adenosine A2 Receptor Agonists; D000818:Animals; D001345:Autoradiography; D001812:Blood-Brain Barrier / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D005260:Female; D008024:Ligands; D051379:Mice; D016716:PC12 Cells; D011485:Protein Binding; D051381:Rats; D043705:Receptor, Adenosine A2A / Q000378:metabolism*; D013552:Swine; D014316:Tritium / Q000737:chemistry*; D014970:Xanthines / Q000737:chemistry / Q000378:metabolism
C113601:3-(3-hydroxypropyl)-8-(3-methoxystyryl)-7-methyl-1-propargylxanthine; D058908:Adenosine A2 Receptor Agonists; D008024:Ligands; D043705:Receptor, Adenosine A2A; D014970:Xanthines; D014316:Tritium